Kuijie Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kuijie Liu has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Yuhong Jiang
Department of General Surgery, the Second Xiangya Hospital, Central South University, Changsha, China
7 shared publicationsXiaoyan Qi
Department of General Surgery, the Second Xiangya Hospital, Central South University, Changsha, China
6 shared publicationsDongju Long
Department of General Surgery The Second Xiangya Hospital of Central South University Changsha China
5 shared publications- Hongliang Yao
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
5 shared publications Qianqian Jin
Department of General Surgery The Second Xiangya Hospital of Central South University Changsha China
5 shared publicationsZuxing Wei
Department of General Surgery, the Second Xiangya Hospital, Central South University, Changsha, China
5 shared publications
Latest Publications
- Open Access
- 13 December 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Caspase 6 deficiency exacerbates inflammatory bowel disease via enterocyte necroptosis and bacterial translocation
Caspase 6 is a pivotal executioner caspase involved in cell death; however, its role in inflammatory bowel disease (IBD) remains incompletely understood. Levels of cleaved caspase 6 were quantified in colonic tissues from IBD patients, and an IBD mouse model was established via DSS induction, incorporating both systemic ( Casp6 KO) and IEC-specific knockout ( Casp6 cKO) strategies. Single-cell RNA sequencing (scRNA-seq) revealed that Casp6 KO enhanced necroptosis in IECs, reducing intestinal endocrine cells and damaging intestinal stem cells. Both in vivo and in vitro studies confirmed that caspase 6 deficiency activates the necroptosis pathway by upregulating RIPK1 in IECs and impairs macrophage bacterial clearance. Importantly, Casp6 KO reduces bactericidal activity in a cathepsin L (CTSL)-dependent manner. These findings demonstrate that preserving caspase 6 activity is essential for necroptosis prevention and effective bacterial clearance, providing new insights for future IBD therapies.
- 13 December 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Open AccessCaspase 6 deficiency exacerbates inflammatory bowel disease via enterocyte necroptosis and bacterial translocation
Caspase 6 is a pivotal executioner caspase involved in cell death; however, its role in inflammatory bowel disease (IBD) remains incompletely understood. Levels of cleaved caspase 6 were quantified in colonic tissues from IBD patients, and an IBD mouse model was established via DSS induction, incorporating both systemic ( Casp6 KO) and IEC-specific knockout ( Casp6 cKO) strategies. Single-cell RNA sequencing (scRNA-seq) revealed that Casp6 KO enhanced necroptosis in IECs, reducing intestinal endocrine cells and damaging intestinal stem cells. Both in vivo and in vitro studies confirmed that caspase 6 deficiency activates the necroptosis pathway by upregulating RIPK1 in IECs and impairs macrophage bacterial clearance. Importantly, Casp6 KO reduces bactericidal activity in a cathepsin L (CTSL)-dependent manner. These findings demonstrate that preserving caspase 6 activity is essential for necroptosis prevention and effective bacterial clearance, providing new insights for future IBD therapies.
- Open Access
- 24 July 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (11) , 8120-8130
Assessment of robotic versus laparoscopic gastrectomy for gastric cancer patients with intraoperative technical complexity: a multicenter retrospective study
Background: While robotic gastrectomy (RG) is increasingly used in gastric cancer surgery, its potential advantages over laparoscopic gastrectomy (LG) in intraoperative technical complexity (ITC) cases remain debated. Methods: This retrospective cohort study included 3534 patients with gastric cancer who underwent radical gastrectomy at eight high-volume hospitals. ITC was defined by any of the following criteria: operative time exceeding the third quartile, intraoperative estimated blood loss ≥400 mL, or conversion to open surgery. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were conducted to compare short- and long-term outcomes. Results: Patients with ITC comprised 25.9% (916/3534) of the cohort (RG: 260, LG: 656). After baseline adjustment, RG and LG groups were comparable in both PSM and IPTW cohorts. RG showed lower overall postoperative complications (11.5% vs. 20.1%, P = 0.003), particularly pneumonia (2.3% vs. 11.0%, P < 0.001) and shorter postoperative hospital stay (9.33 ± 4.41 vs. 10.77 ± 5.91 days, P < 0.001) compared to LG. These differences remained significant after PSM and IPTW analysis. The 3-year overall survival (83% vs. 78.8%, P = 0.15), disease-free survival (81.9% vs. 76.2%, P = 0.073), and cumulative recurrence risk (16.9% vs. 20%, P = 0.26) were comparable between RG and LG groups, consistent after PSM and IPTW. Multivariate analysis indicated that the surgical approach was not an independent factor influencing technical complexity. Conclusions: For patients with ITC, RG demonstrated superior short-term and comparable long-term outcomes than LG.
- 24 July 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (11) , 8120-8130
Open AccessAssessment of robotic versus laparoscopic gastrectomy for gastric cancer patients with intraoperative technical complexity: a multicenter retrospective study
Background: While robotic gastrectomy (RG) is increasingly used in gastric cancer surgery, its potential advantages over laparoscopic gastrectomy (LG) in intraoperative technical complexity (ITC) cases remain debated. Methods: This retrospective cohort study included 3534 patients with gastric cancer who underwent radical gastrectomy at eight high-volume hospitals. ITC was defined by any of the following criteria: operative time exceeding the third quartile, intraoperative estimated blood loss ≥400 mL, or conversion to open surgery. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were conducted to compare short- and long-term outcomes. Results: Patients with ITC comprised 25.9% (916/3534) of the cohort (RG: 260, LG: 656). After baseline adjustment, RG and LG groups were comparable in both PSM and IPTW cohorts. RG showed lower overall postoperative complications (11.5% vs. 20.1%, P = 0.003), particularly pneumonia (2.3% vs. 11.0%, P < 0.001) and shorter postoperative hospital stay (9.33 ± 4.41 vs. 10.77 ± 5.91 days, P < 0.001) compared to LG. These differences remained significant after PSM and IPTW analysis. The 3-year overall survival (83% vs. 78.8%, P = 0.15), disease-free survival (81.9% vs. 76.2%, P = 0.073), and cumulative recurrence risk (16.9% vs. 20%, P = 0.26) were comparable between RG and LG groups, consistent after PSM and IPTW. Multivariate analysis indicated that the surgical approach was not an independent factor influencing technical complexity. Conclusions: For patients with ITC, RG demonstrated superior short-term and comparable long-term outcomes than LG.
- Open Access
- 8 April 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 79, 783-799
Inflammation-driven biomimetic nano-polyphenol drug delivery system alleviates severe acute pancreatitis by inhibiting macrophage PANoptosis and pancreatic enzymes oversecretion
- 8 April 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 79, 783-799
Open AccessInflammation-driven biomimetic nano-polyphenol drug delivery system alleviates severe acute pancreatitis by inhibiting macrophage PANoptosis and pancreatic enzymes oversecretion
- 9 September 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (5) , 1525-1539
Biomimetic modification of macrophage membrane-coated prussian blue nanoparticles loaded with SN-38 to treat colorectal cancer by photothermal-chemotherapy
SN-38 is the active metabolite of irinotecan and acts as an effective topoisomerase I inhibitor with therapeutic effects on many malignant tumors, including some drug-resistant cancers. However, the poor solubility, low bioavailability, and severe dose-dependent toxicity limits the clinical application of SN-38. Currently, emerging macrophage membrane-coated nanoparticles provide an efficient biomimetic approach to develop novel SN-38 formulations for the reduction of its side effects. Photothermal therapy (PTT) is a promising methods in tumor treatment to thermally ablate tumors using various materials such Prussian blue nanoparticles (NPs) and can combined with chemotherapy to synergistically work. There is no report that combined SN38 and photothermal therapy for the treatment of colorectal cancer (CRC). SN38-PB@CM NPs were constructed by loading SN-38 into macrophage cell membrane-coated hollow mesoporous Prussian blue (PB) NPs. The morphology, size and zeta potential were evaluated by transmission microscopy and dynamic light scatter (DLS). Coomassie bright blue staining was performed to assess total protein profile. The photothermal properties of it were also investigated via near-infrared imaging. CCK8 and calcein-AM/PI staining were used to evaluate cell viability. Flow cytometry was performed to assess cell apoptosis. The fluorescent microscopy was used to observe cellular uptake of SN38-PB@CM NPs to assess its internalization in vitro. The biodistribution, tumor-targeting efficacy, antitumor efficacy and safety of SN38-PB@CM NPs in vivo were assessed in CT26 tumor-bearing mice via In Vivo Imaging System. SN38-PB@CM NPs were successfully constructed and exhibited a uniform size distribution (140.5 ± 4.3 nm) and an excellent drug-loading capacity (5.61 ± 0.64%). SN38-PB@CM NPs showed stable release properties within 72 h. It can also enhance the selective intracellular delivery of SN38 in vitro and showed good near-infrared (NIR) photothermal properties. And the NPs showed excellent tumor targeting, effective photothermal therapy, improved biosafety and antitumor efficacy on CT26-bearing mice. Multifunctional SN38-PB@CM NPs could achieve improved biosafety, great tumor-targeting, high-efficiency PTT and excellent antitumor efficacy, which provided a promising and attractive combination therapy for the treatment of CRC. Graphic Abstract
- 9 September 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (5) , 1525-1539
Biomimetic modification of macrophage membrane-coated prussian blue nanoparticles loaded with SN-38 to treat colorectal cancer by photothermal-chemotherapy
SN-38 is the active metabolite of irinotecan and acts as an effective topoisomerase I inhibitor with therapeutic effects on many malignant tumors, including some drug-resistant cancers. However, the poor solubility, low bioavailability, and severe dose-dependent toxicity limits the clinical application of SN-38. Currently, emerging macrophage membrane-coated nanoparticles provide an efficient biomimetic approach to develop novel SN-38 formulations for the reduction of its side effects. Photothermal therapy (PTT) is a promising methods in tumor treatment to thermally ablate tumors using various materials such Prussian blue nanoparticles (NPs) and can combined with chemotherapy to synergistically work. There is no report that combined SN38 and photothermal therapy for the treatment of colorectal cancer (CRC). SN38-PB@CM NPs were constructed by loading SN-38 into macrophage cell membrane-coated hollow mesoporous Prussian blue (PB) NPs. The morphology, size and zeta potential were evaluated by transmission microscopy and dynamic light scatter (DLS). Coomassie bright blue staining was performed to assess total protein profile. The photothermal properties of it were also investigated via near-infrared imaging. CCK8 and calcein-AM/PI staining were used to evaluate cell viability. Flow cytometry was performed to assess cell apoptosis. The fluorescent microscopy was used to observe cellular uptake of SN38-PB@CM NPs to assess its internalization in vitro. The biodistribution, tumor-targeting efficacy, antitumor efficacy and safety of SN38-PB@CM NPs in vivo were assessed in CT26 tumor-bearing mice via In Vivo Imaging System. SN38-PB@CM NPs were successfully constructed and exhibited a uniform size distribution (140.5 ± 4.3 nm) and an excellent drug-loading capacity (5.61 ± 0.64%). SN38-PB@CM NPs showed stable release properties within 72 h. It can also enhance the selective intracellular delivery of SN38 in vitro and showed good near-infrared (NIR) photothermal properties. And the NPs showed excellent tumor targeting, effective photothermal therapy, improved biosafety and antitumor efficacy on CT26-bearing mice. Multifunctional SN38-PB@CM NPs could achieve improved biosafety, great tumor-targeting, high-efficiency PTT and excellent antitumor efficacy, which provided a promising and attractive combination therapy for the treatment of CRC. Graphic Abstract
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (5) , 1707-1728
Hspb1 protects against severe acute pancreatitis by attenuating apoptosis and ferroptosis via interacting with Anxa2 to restore the antioxidative activity of Prdx1
Acute pancreatitis (AP) is a common abdominal disease that typically resolves on its own, but the mortality rate dramatically increases when it progresses to severe acute pancreatitis (SAP). In this study, we investigated the molecular mechanism underlying the development of SAP from AP. We utilized two SAP models induced by pancreatic duct ligation and caerulein administration. Transcriptomic and proteomic analyses were subsequently performed to determine the mRNA and protein expression profiles of pancreatic samples from SAP and AP model and normal mice.
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (5) , 1707-1728
Open AccessHspb1 protects against severe acute pancreatitis by attenuating apoptosis and ferroptosis via interacting with Anxa2 to restore the antioxidative activity of Prdx1
Acute pancreatitis (AP) is a common abdominal disease that typically resolves on its own, but the mortality rate dramatically increases when it progresses to severe acute pancreatitis (SAP). In this study, we investigated the molecular mechanism underlying the development of SAP from AP. We utilized two SAP models induced by pancreatic duct ligation and caerulein administration. Transcriptomic and proteomic analyses were subsequently performed to determine the mRNA and protein expression profiles of pancreatic samples from SAP and AP model and normal mice.
- 30 August 2023
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 23 (3) , 1-14
Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway
Hepatocellular carcinoma (HCC) is the tumor with the second highest mortality rate worldwide. Recent research data show that KIF11, a member of the kinesin family (KIF), plays an important role in the progression of various tumors. However, its expression and molecular mechanism in HCC remain elusive. Here, we evaluated the potential role of KIF11 in HCC. The effect of KIF11 was evaluated using the hepatocellular carcinoma cell lines, LM3 and Huh7, after genetic or pharmacological treatment. Evaluating the role of KIF11 in the xenograft animal models using its specific inhibitor. The role of KIF11 was systematically evaluated using specimens obtained from the aforementioned animal and cell models after various in vivo and in vitro experiments. The clinicopathological analysis showed that KIF11 was expressed at high levels in patients with hepatocellular carcinoma. Cell experiments in vitro showed that KIF11 deficiency significantly slowed the proliferation of liver tumor cells. And in the experiment using liver cancer cells overexpressing OCT4, overexpression of OCT4 substantially increased the proliferation of tumor cells compared with tumor cells with KIF11 knockdown alone. Both in vitro cell experiment and in vivo xenotransplantation tumor experiment showed that monastrol, an inhibitor of KIF11, could effectively delay the proliferation and migration of tumor cells. Based on these results, KIF11 is expressed at high levels in hepatocellular carcinoma and promotes tumor proliferation in an OCT4-dependent manner. KIF11 may become a therapeutic target for hepatocellular carcinoma, and its inhibitor monastrol may become a clinical antitumor drug.
- 30 August 2023
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 23 (3) , 1-14
Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway
Hepatocellular carcinoma (HCC) is the tumor with the second highest mortality rate worldwide. Recent research data show that KIF11, a member of the kinesin family (KIF), plays an important role in the progression of various tumors. However, its expression and molecular mechanism in HCC remain elusive. Here, we evaluated the potential role of KIF11 in HCC. The effect of KIF11 was evaluated using the hepatocellular carcinoma cell lines, LM3 and Huh7, after genetic or pharmacological treatment. Evaluating the role of KIF11 in the xenograft animal models using its specific inhibitor. The role of KIF11 was systematically evaluated using specimens obtained from the aforementioned animal and cell models after various in vivo and in vitro experiments. The clinicopathological analysis showed that KIF11 was expressed at high levels in patients with hepatocellular carcinoma. Cell experiments in vitro showed that KIF11 deficiency significantly slowed the proliferation of liver tumor cells. And in the experiment using liver cancer cells overexpressing OCT4, overexpression of OCT4 substantially increased the proliferation of tumor cells compared with tumor cells with KIF11 knockdown alone. Both in vitro cell experiment and in vivo xenotransplantation tumor experiment showed that monastrol, an inhibitor of KIF11, could effectively delay the proliferation and migration of tumor cells. Based on these results, KIF11 is expressed at high levels in hepatocellular carcinoma and promotes tumor proliferation in an OCT4-dependent manner. KIF11 may become a therapeutic target for hepatocellular carcinoma, and its inhibitor monastrol may become a clinical antitumor drug.
- Open Access
- 25 August 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-18
The anoikis-related gene signature predicts survival accurately in colon adenocarcinoma
Colon adenocarcinoma (COAD) is a serious public health problem, the third most common cancer and the second most deadly cancer in the world. About 9.4% of cancer-related deaths in 2020 were due to COAD. Anoikis is a specialized form of programmed cell death that plays an important role in tumor invasion and metastasis. The presence of anti-anoikis factors is associated with tumor aggressiveness and drug resistance. Various bioinformatic methods, such as differential expression analysis, and functional annotation analysis, machine learning, were used in this study. RNA-sequencing and clinical data from COAD patients were obtained from the Gene expression omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Construction of a prognostic nomogram for predicting overall survival (OS) using multivariate analysis and Lasso-Cox regression. Immunohistochemistry (IHC) was our method of validating the expression of seven genes that are linked to anoikis in COAD. We identified seven anoikis-related genes as predictors of COAD survival and prognosis, and confirmed their accuracy in predicting colon adenocarcinoma prognosis by KM survival curves and ROC curves. A seven-gene risk score consisting of NAT1, CDC25C, ATP2A3, MMP3, EEF1A2, PBK, and TIMP1 showed strong prognostic value. Meanwhile, we made a nomogram to predict the survival rate of COAD patients. The immune infiltration assay showed T cells. CD4 memory. Rest and macrophages. M0 has a higher proportion in COAD, and 11 genes related to tumor immunity are important. GDSC2-based drug susceptibility analysis showed that 6 out of 198 drugs were significant in COAD. Anoikis-related genes have potential value in predicting the prognosis of COAD and provide clues for developing new therapeutic strategies for COAD. Immune infiltration and drug susceptibility results provide important clues for finding new personalized treatment options for COAD. These findings also suggest possible mechanisms that may affect prognosis. These results are the starting point for planning individualized treatment and managing patient outcomes.
- 25 August 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-18
Open AccessThe anoikis-related gene signature predicts survival accurately in colon adenocarcinoma
Colon adenocarcinoma (COAD) is a serious public health problem, the third most common cancer and the second most deadly cancer in the world. About 9.4% of cancer-related deaths in 2020 were due to COAD. Anoikis is a specialized form of programmed cell death that plays an important role in tumor invasion and metastasis. The presence of anti-anoikis factors is associated with tumor aggressiveness and drug resistance. Various bioinformatic methods, such as differential expression analysis, and functional annotation analysis, machine learning, were used in this study. RNA-sequencing and clinical data from COAD patients were obtained from the Gene expression omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Construction of a prognostic nomogram for predicting overall survival (OS) using multivariate analysis and Lasso-Cox regression. Immunohistochemistry (IHC) was our method of validating the expression of seven genes that are linked to anoikis in COAD. We identified seven anoikis-related genes as predictors of COAD survival and prognosis, and confirmed their accuracy in predicting colon adenocarcinoma prognosis by KM survival curves and ROC curves. A seven-gene risk score consisting of NAT1, CDC25C, ATP2A3, MMP3, EEF1A2, PBK, and TIMP1 showed strong prognostic value. Meanwhile, we made a nomogram to predict the survival rate of COAD patients. The immune infiltration assay showed T cells. CD4 memory. Rest and macrophages. M0 has a higher proportion in COAD, and 11 genes related to tumor immunity are important. GDSC2-based drug susceptibility analysis showed that 6 out of 198 drugs were significant in COAD. Anoikis-related genes have potential value in predicting the prognosis of COAD and provide clues for developing new therapeutic strategies for COAD. Immune infiltration and drug susceptibility results provide important clues for finding new personalized treatment options for COAD. These findings also suggest possible mechanisms that may affect prognosis. These results are the starting point for planning individualized treatment and managing patient outcomes.
- 6 November 2022
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 17 (3) , 905-914
A propensity score matching study of totally robotic right hemicolectomy versus robot-assisted right hemicolectomy
To compare and analyze the differences in safety, feasibility and short-term efficacy between robot-assisted right hemicolectomy (RARH) and totally robotic right hemicolectomy (TRRH). We collected the information of 184 patients who underwent right hemicolectomy in the Second Xiangya Hospital of Central South University from July 2016 to December 2021. We matched 148 patients (74 with robot-assisted right hemicolectomy and 74 with totally robotic right hemicolectomy) to conduct a retrospective analysis of their clinical outcomes. The incision lengths were 5.14 ± 0.60 cm in the RARH group and 4.74 ± 0.55 cm in the TRRH (p < 0.001). The blood losses were 86.28 ± 52.57 mL in the RARH group and 69.19 ± 44.78 mL in the TRRH (p = 0.035). The operative times were 197.50 min (171.25–242.25) in the RARH group and 160.00 min (145.00–188.75) in the TRRH (p < 0.001). The postoperative hospital stays were 11.18 ± 4.32 days in the RARH group and 9.53 ± 4.42 days in the TRRH (p = 0.023). The NRS pain scores were 3.05 ± 0.23 in the RARH group and 2.96 ± 0.26 in the TRRH (p = 0.019). The abdominal drainage extraction times were 7.54 ± 1.44 days in the RARH group and 7.00 ± 1.25 days in the TRRH (p = 0.016). Postoperative complications in the RARH group are fewer than TRRH (p = 0.033). TRRH is safe and feasible. Compared with RARHs, the TRRHs resulted in shorter incision lengths, operative times, intraoperative blood losses, postoperative hospital stays, first flatus times, first liquid diet times, and drainage tube removal times, and they improved NRS pain scores and postoperative complication frequencies.
- 6 November 2022
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 17 (3) , 905-914
A propensity score matching study of totally robotic right hemicolectomy versus robot-assisted right hemicolectomy
To compare and analyze the differences in safety, feasibility and short-term efficacy between robot-assisted right hemicolectomy (RARH) and totally robotic right hemicolectomy (TRRH). We collected the information of 184 patients who underwent right hemicolectomy in the Second Xiangya Hospital of Central South University from July 2016 to December 2021. We matched 148 patients (74 with robot-assisted right hemicolectomy and 74 with totally robotic right hemicolectomy) to conduct a retrospective analysis of their clinical outcomes. The incision lengths were 5.14 ± 0.60 cm in the RARH group and 4.74 ± 0.55 cm in the TRRH (p < 0.001). The blood losses were 86.28 ± 52.57 mL in the RARH group and 69.19 ± 44.78 mL in the TRRH (p = 0.035). The operative times were 197.50 min (171.25–242.25) in the RARH group and 160.00 min (145.00–188.75) in the TRRH (p < 0.001). The postoperative hospital stays were 11.18 ± 4.32 days in the RARH group and 9.53 ± 4.42 days in the TRRH (p = 0.023). The NRS pain scores were 3.05 ± 0.23 in the RARH group and 2.96 ± 0.26 in the TRRH (p = 0.019). The abdominal drainage extraction times were 7.54 ± 1.44 days in the RARH group and 7.00 ± 1.25 days in the TRRH (p = 0.016). Postoperative complications in the RARH group are fewer than TRRH (p = 0.033). TRRH is safe and feasible. Compared with RARHs, the TRRHs resulted in shorter incision lengths, operative times, intraoperative blood losses, postoperative hospital stays, first flatus times, first liquid diet times, and drainage tube removal times, and they improved NRS pain scores and postoperative complication frequencies.
- Open Access
- 13 September 2022
- Published by Wiley in Cancer Science
- Vol. 113 (11) , 3826-3837
3D matrix promotes cell dedifferentiation into colorectal cancer stem cells via integrin/cytoskeleton/glycolysis signaling
The potential for tumor occurrence triggered by cancer stem cells (CSCs) has emerged as a significant challenge for human colorectal cancer therapy. However, the underlying mechanism of CSC development remains controversial. Our study provided evidence that the bulk of tumor cells could dedifferentiate to CSCs and reacquire CSC‐like phenotypes if cultured in the presence of extracellular matrix reagents, such as Matrigel and fibrin gels. In these 3D gels, CD133− colorectal cancer cells can regain tumorigenic potential and stem‐like phenotypes. Mechanistically, the 3D extracellular matrix could mediate cytoskeletal F‐actin bundling through biomechanical force associated receptors integrin β1 (ITGB1), contributing to the release of E3 ligase tripartite motif protein 11 (TRIM11) from cytoskeleton and degradation of the glycolytic rate‐limiting enzyme phosphofructokinase (PFK). Consequently, PFK inhibition resulted in enhanced glycolysis and upregulation of hypoxia‐inducible factor 1 (HIF1α), thereby promoting the reprogramming of stem cell transcription factors and facilitating tumor progression in patients. This study provided novel insights into the role of the extracellular matrix in the regulation of CSC dedifferentiation in a cytoskeleton/glycolysis‐dependent manner.
- 13 September 2022
- Published by Wiley in Cancer Science
- Vol. 113 (11) , 3826-3837
Open Access3D matrix promotes cell dedifferentiation into colorectal cancer stem cells via integrin/cytoskeleton/glycolysis signaling
The potential for tumor occurrence triggered by cancer stem cells (CSCs) has emerged as a significant challenge for human colorectal cancer therapy. However, the underlying mechanism of CSC development remains controversial. Our study provided evidence that the bulk of tumor cells could dedifferentiate to CSCs and reacquire CSC‐like phenotypes if cultured in the presence of extracellular matrix reagents, such as Matrigel and fibrin gels. In these 3D gels, CD133− colorectal cancer cells can regain tumorigenic potential and stem‐like phenotypes. Mechanistically, the 3D extracellular matrix could mediate cytoskeletal F‐actin bundling through biomechanical force associated receptors integrin β1 (ITGB1), contributing to the release of E3 ligase tripartite motif protein 11 (TRIM11) from cytoskeleton and degradation of the glycolytic rate‐limiting enzyme phosphofructokinase (PFK). Consequently, PFK inhibition resulted in enhanced glycolysis and upregulation of hypoxia‐inducible factor 1 (HIF1α), thereby promoting the reprogramming of stem cell transcription factors and facilitating tumor progression in patients. This study provided novel insights into the role of the extracellular matrix in the regulation of CSC dedifferentiation in a cytoskeleton/glycolysis‐dependent manner.
- Open Access
- 11 August 2022
- Published by Springer Nature in Research Square
A propensity score matching study of totally robotic Right Hemicolectomy versus robot-assisted Right Hemicolectomy
Objective To compare and analyze the differences in safety, feasibility and short-term efficacy between robot-assisted and totally robotic surgery in Right Hemicolectomy. Methods A retrospective analysis was conducted on the clinical data of 184 patients who underwent right hemicolectomy in The Second Xiangya Hospital of Central South University from July 2016 to December 2021. 148 patients were matched (including 74 cases of robot-assisted right hemicolectomy (TRAH) and 74 cases of totally robotic right hemicolectomy (TRRH)). The general information, surgical and pathological results and complications of patients were collected and analyzed. Results The incision length was 5.14 ± 0.60cm in the robot-assisted group 4.74 ± 0.55cm in the totally robotic group (p < 0.001). The blood loss was 86.28 ± 52.57 ml in the robot-assisted group and 69.19 ± 44.78 ml in the totally robotic group (p = 0.035).The operative time of the robot-assisted group was 197.50 (171.25, 242.25) min, and that of the totally robotic group was 160.00 (145.00, 188.75) min (p < 0.001).The postoperative hospital stay was 11.18 ± 4.32 days in the robot-assisted group and 9.53 ± 4.42 days in the totally robotic group (p = 0.023). NRS pain scores were 3.05 ± 0.23 for the robot-assisted group and 2.96 ± 0.26 for the totally robotic group (p = 0.019). The extraction time of abdominal drainage was 7.54 ± 1.44 days in the robot-assisted group and 7.00 ± 1.25 days in the totally robotic group (p = 0.016). postoperative complications in the robot-assisted group were as follows: Urinary retention 1 (1.4%), chylous fistula 1 (1.4%), wound complications 3 (4.1%), postoperative intestinal obstruction 1 (1.4%), postoperative anastomosis 3 (4.1%), other complications 4 (5.4%);postoperative complications in the totally robotic group included 0 cases of urinary retention, 7 cases of chylous fistula (9.3%), 1 case of wound complication (1.3%), 0 cases of postoperative intestinal obstruction, 2 cases of postoperative anastomotic complications (2.7%), and 0 cases of other complications. Conclusions Complete robotic right hemicolectomy in the hands of an experienced colorectal surgeon is safe and feasible. Compared with robot-assisted right hemicolectomy, the totally robotic right hemicolectomy group has certain advantages in incision length, operative time, intraoperative blood loss, postoperative hospital stay, first exhaust time, first liquid diet time, Time of drainage tube removal, NRS pain score and postoperative complications.
- 11 August 2022
- Published by Springer Nature in Research Square
Open AccessA propensity score matching study of totally robotic Right Hemicolectomy versus robot-assisted Right Hemicolectomy
Objective To compare and analyze the differences in safety, feasibility and short-term efficacy between robot-assisted and totally robotic surgery in Right Hemicolectomy. Methods A retrospective analysis was conducted on the clinical data of 184 patients who underwent right hemicolectomy in The Second Xiangya Hospital of Central South University from July 2016 to December 2021. 148 patients were matched (including 74 cases of robot-assisted right hemicolectomy (TRAH) and 74 cases of totally robotic right hemicolectomy (TRRH)). The general information, surgical and pathological results and complications of patients were collected and analyzed. Results The incision length was 5.14 ± 0.60cm in the robot-assisted group 4.74 ± 0.55cm in the totally robotic group (p < 0.001). The blood loss was 86.28 ± 52.57 ml in the robot-assisted group and 69.19 ± 44.78 ml in the totally robotic group (p = 0.035).The operative time of the robot-assisted group was 197.50 (171.25, 242.25) min, and that of the totally robotic group was 160.00 (145.00, 188.75) min (p < 0.001).The postoperative hospital stay was 11.18 ± 4.32 days in the robot-assisted group and 9.53 ± 4.42 days in the totally robotic group (p = 0.023). NRS pain scores were 3.05 ± 0.23 for the robot-assisted group and 2.96 ± 0.26 for the totally robotic group (p = 0.019). The extraction time of abdominal drainage was 7.54 ± 1.44 days in the robot-assisted group and 7.00 ± 1.25 days in the totally robotic group (p = 0.016). postoperative complications in the robot-assisted group were as follows: Urinary retention 1 (1.4%), chylous fistula 1 (1.4%), wound complications 3 (4.1%), postoperative intestinal obstruction 1 (1.4%), postoperative anastomosis 3 (4.1%), other complications 4 (5.4%);postoperative complications in the totally robotic group included 0 cases of urinary retention, 7 cases of chylous fistula (9.3%), 1 case of wound complication (1.3%), 0 cases of postoperative intestinal obstruction, 2 cases of postoperative anastomotic complications (2.7%), and 0 cases of other complications. Conclusions Complete robotic right hemicolectomy in the hands of an experienced colorectal surgeon is safe and feasible. Compared with robot-assisted right hemicolectomy, the totally robotic right hemicolectomy group has certain advantages in incision length, operative time, intraoperative blood loss, postoperative hospital stay, first exhaust time, first liquid diet time, Time of drainage tube removal, NRS pain score and postoperative complications.